As a physician who has spent years managing patients with persistent pain, I often encounter the same frustrating cycle. A patient arrives with unrelenting back pain that has lasted for months. They describe not just physical discomfort but a deepening sense of hopelessness, fatigue, and withdrawal from life. Is the pain causing the depression, or did underlying depressive symptoms amplify an initially manageable ache into something chronic and debilitating? It is the medical equivalent of the classic chicken-or-egg dilemma: which came first?

The evidence on the pain-depression link is clear. This is not a one-way street. Chronic pain and depression share overlapping mechanisms of disease and respond to many of the same treatments. They fuel each other in a bidirectional loop that complicates care, worsens outcomes, and strains our health care system. Recognizing this interplay is essential, especially as we deal with workforce shortages and shifting priorities in mental health training.

A bidirectional relationship backed by data

Large-scale studies consistently demonstrate that chronic pain and depression do not merely coexist, as they actively exacerbate one another. A 2024 analysis of two major aging cohorts found a modest but statistically significant bidirectional association: chronic pain modestly increased the risk of subsequent depressive symptoms, while baseline depressive symptoms modestly raised the likelihood of developing chronic pain. Similar 20-year longitudinal data and pooled analyses of national cohorts confirm the pattern across age groups and pain types, including back pain.

Prevalence data underscore the scale of the problem. Among adults with chronic pain, approximately 39 percent experience clinically significant depressive symptoms, far higher than in the general population. In pain clinics and specialized settings, rates climb even higher, sometimes exceeding 50 percent. Patients with fibromyalgia show some of the strongest overlaps, with over half reporting both conditions.

Why does this happen? Depression lowers pain tolerance and heightens pain perception through altered central processing. Conversely, unrelenting pain triggers neuroinflammatory changes, sleep disruption, and loss of function that erode mood and motivation. It is a vicious cycle: pain begets depression, which in turn intensifies pain, leading to more functional impairment and deeper despair.

Shared neurobiological pathways

The “chicken or egg” question has a neurobiological answer. Both conditions arise from overlapping brain circuitry and chemistry. Key regions, including the amygdala, anterior cingulate cortex, hippocampus, prefrontal cortex, and insula, process both emotional distress and pain signals. Neurotransmitter systems involving serotonin and norepinephrine are dysregulated in both disorders, explaining why interventions targeting these pathways help either condition. Brain-derived neurotrophic factor (BDNF) levels drop in the hippocampus in both states, contributing to impaired neuroplasticity. Chronic stress activates the hypothalamic-pituitary-adrenal axis, perpetuating inflammation that links the two.

Functional imaging studies further illustrate the shared burden. Pain accompanied by depression often shows heightened right amygdala activity, while depression with prominent pain correlates with left dorsolateral prefrontal cortex hypoactivity, which are the regions critical for emotional regulation and pain modulation. These common substrates mean that untreated pain can literally reshape brain function in ways that mimic or worsen depressive neurobiology, and vice versa.

Treatment overlap: one stone, two birds

The mechanistic overlap translates directly into clinical practice. Certain medications address both pain and depression simultaneously, offering efficient dual benefit.

Duloxetine (Cymbalta), a serotonin-norepinephrine reuptake inhibitor (SNRI), is Food and Drug Administration (FDA) approved for major depressive disorder, generalized anxiety, and several chronic pain conditions, including diabetic neuropathy, fibromyalgia, and musculoskeletal pain. Meta-analyses confirm it reduces pain intensity, improves physical function, and lifts mood at standard doses (60 mg daily).

Nortriptyline, a tricyclic antidepressant, similarly demonstrates strong efficacy for neuropathic pain and depression. Real-world comparative studies rank it among the top performers for pain relief with acceptable tolerability, often outperforming or matching duloxetine in head-to-head utility analyses. Both drugs work at doses that simultaneously target mood and pain pathways, nortriptyline often at lower doses for analgesia than for full antidepressant effect.

This overlap is not limited to pharmacology. Providers who routinely treat chronic pain quickly become adept at recognizing and managing depressive symptoms that amplify pain reporting. Psychiatric clinicians, in turn, frequently encounter patients whose somatic complaints represent pain intensified by mood disorders. Integrated care, whether in multidisciplinary pain clinics or collaborative models, leverages this expertise to break the cycle more effectively than siloed approaches.

Workforce realities and the case for prevention

Recent years have seen substantial investment in training mid-level providers (nurse practitioners and physician assistants) to address the mental health crisis. This is necessary and overdue. Yet it risks an unintended consequence: fewer clinicians willing or trained to manage complex chronic pain patients, whose needs extend beyond mental health screening into nuanced multimodal care.

We must moderate this shift. Chronic pain should be addressed proactively, and just before it evolves into a secondary mental health crisis. Early, aggressive pain management (pharmacologic, interventional, behavioral, and rehabilitative) can prevent the downward spiral of depression. Treating the “egg” (pain) early may avert the “chicken” (depression) altogether. This preventive mindset aligns with evidence that bidirectional comorbidity worsens prognosis when either condition is ignored.

Primary care clinicians, pain specialists, and psychiatrists already overlap in skill sets. Expanding pain education within psychiatry residencies and mental health training programs, as some institutions have begun to do, would further bridge the gap. Conversely, ensuring pain-focused providers maintain competence in depression screening and basic psychopharmacology prevents unnecessary referrals and delays.

Breaking the cycle: a call to integrated action

The chicken-or-egg riddle of chronic pain and depression has no single starting point, but it does have a clear solution: treat both conditions concurrently from the outset. Screen every chronic pain patient for depression and anxiety using validated tools. Consider dual-action antidepressants like duloxetine or nortriptyline early when appropriate. Refer for multidisciplinary care when pain persists despite initial therapy. And advocate for policies that support early pain intervention rather than waiting for psychiatric decompensation.

As clinicians, we cannot afford to view pain and mood disorders as separate silos. Our patients live in the messy reality where one begets the other. By embracing their shared biology and overlapping treatments, we can interrupt the cycle, improve quality of life, and use our limited workforce more effectively.

The next time you see a patient trapped in this loop, remember: it does not matter which came first. What matters is that we intervene before the cycle becomes unbreakable. Early, integrated care is not just good medicine, as it is the practical answer to a very old riddle.

Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.

Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.

Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.